SCHEMBL9324289

SCHEMBL9324289

CCOC(=O)CCn1ccc2ccccc21

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.61
CREBBP Q92793 1/20 0.60
TNF P01375 2/20 0.59
CDK4 P11802 4/20 0.54
CCND1 P24385 4/20 0.54
MAPK1 P28482 2/20 0.54
PTPN1 P18031 1/20 0.51
KMT2A Q03164 2/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2C19 P33261 1/20 0.50
HTR2A P28223 1/20 0.49
HTR2C P28335 1/20 0.49
TUBB4A P04350 1/20 0.48
TUBB P07437 1/20 0.48
TUBA3C P0DPH7 1/20 0.48
TUBA1B P68363 1/20 0.48
TUBA4A P68366 1/20 0.48
TUBB4B P68371 1/20 0.48
TUBB3 Q13509 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8792687 0.92 TNF (0.70) LMNACREBBPTNFCDK4CCND1
SCHEMBL3864912 0.85 KMT2A (0.61) LMNATNFCDK4CCND1MAPK1
SCHEMBL30379991 0.85 KMT2A (0.61) LMNATNFCDK4CCND1MAPK1
SCHEMBL2037341 0.85 LMNA (0.65) LMNACDK4CCND1MAPK1KMT2A
SCHEMBL9324243 0.85 LMNA (0.57) LMNACDK4CCND1MAPK1KMT2A
SCHEMBL9324414 0.85 LMNA (0.57) LMNACREBBPCDK4CCND1MAPK1
SCHEMBL4473320 0.82 TNF (0.53) LMNACREBBPTNFKMT2ATUBB4A
SCHEMBL10203635 0.81 LMNA (0.69) LMNACDK4CCND1MAPK1KMT2A
SCHEMBL3596244 0.81 LMNA (0.60) LMNACDK4CCND1MAPK1KMT2A
SCHEMBL20553630 0.81 TNF (0.52) LMNACREBBPTNFHTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2670733-B1 N-HYDROXYBENZAMIDE DERIVATIVES AS HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME UNIV ILLINOIS (US) 2019-04-10 EP disclosed
US-RE47009-E1 HDAC inhibitors and therapeutic methods using the same THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) 2018-08-28 US disclosed
US-9249087-B2 HDAC inhibitors and therapeutic methods using the same THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2016-02-02 US disclosed
US-20140128408-A1 HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2014-05-08 US disclosed
EP-2670733-A2 HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME The Board of Trustees of the University of Illinois (US) 2013-12-11 EP disclosed
WO-2012106343-A2 HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2012-08-09 WO disclosed
EP-0583004-A1 Silver halide photographic material FUJI PHOTO FILM CO., LTD. (JP) 1994-02-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140128408-A1 HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME HDAC1, HDAC9, HDAC8 LMNA 2543/4885CREBBP 106/4885TNF 3620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.